Xenon Pharmaceuticals Inc. (XENE)
NASDAQ: XENE · Real-Time Price · USD
42.75
-1.04 (-2.37%)
Mar 4, 2026, 10:08 AM EST - Market open
Xenon Pharmaceuticals Stock Forecast
Stock Price Forecast
The 10 analysts with 12-month price forecasts for Xenon Pharmaceuticals stock have an average target of 53.7, with a low estimate of 43 and a high estimate of 62. The average target predicts an increase of 25.61% from the current stock price of 42.75.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Xenon Pharmaceuticals stock from 10 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 3 | 3 |
| Buy | 6 | 6 | 6 | 6 | 7 | 7 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 11 | 11 | 11 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Strong Buy Maintains $55 → $58 | Strong Buy | Maintains | $55 → $58 | +35.67% | Feb 27, 2026 |
| Wells Fargo | Wells Fargo | Buy Maintains $48 → $49 | Buy | Maintains | $48 → $49 | +14.62% | Feb 27, 2026 |
| Wolfe Research | Wolfe Research | Buy Initiates $60 | Buy | Initiates | $60 | +40.35% | Feb 24, 2026 |
| JP Morgan | JP Morgan | Buy Maintains $60 → $62 | Buy | Maintains | $60 → $62 | +45.03% | Jan 9, 2026 |
| Wells Fargo | Wells Fargo | Buy Maintains $44 → $48 | Buy | Maintains | $44 → $48 | +12.28% | Dec 11, 2025 |
Financial Forecast
Revenue This Year
5.10M
from 7.50M
Decreased by -32.00%
Revenue Next Year
89.04M
from 5.10M
Increased by 1,645.94%
EPS This Year
-4.82
from -4.36
EPS Next Year
-4.65
from -4.82
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 26.3M | 263.5M | |||
| Avg | 5.1M | 89.0M | |||
| Low | n/a | 13.7M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 250.0% | 5,066.5% | |||
| Avg | -32.0% | 1,645.9% | |||
| Low | - | 169.1% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -4.15 | -1.92 | |||
| Avg | -4.82 | -4.65 | |||
| Low | -5.63 | -5.80 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.